CQ1373
CQ1373 is a potent RET inhibitor, demonstrating cellular potency with IC50 values of 13.0, 25.7 and 28.4 nM against BaF3 cells expressing CCDC6-RET, CCDC6-RET-G810C and CCDC6-RET-G810R, respectively. CQ1373 exhibits good selectivity toward wild-type RET and solvent front mutants G810C/R with IC50 values of 4.2, 7.1 and 32.4 nM, respectively. CQ1373 inhibits RET phosphorylation and downstream signaling through SHC. CQ1373 induces Apoptosis and cell cycle arrest in BaF3 cells. CQ1373 exhibits anti-tumor efficacy and can be used for cancer research[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; RET
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
CC(C)(C(F)(F)F)C1=CC(NC(NC2=C(Cl)C=C(/C=C/C3=C(C4=CN=CC(OC)=C4)C=NN3)C=C2)=O)=NO1
Molecular Formula
C25H22ClF3N6O3
Molecular Weight
546.93
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Methyl 4- (trifluoromethyl) -1,4-dihydroquinoline-3-carboxylate
Methyl 4- (trifluoromethyl) -1,4-dihydroquinoline-3-carboxylate
Lentiviral human KDELR3 shRNA (UAS) - Lentiviral human KDELR3 shRNA (UAS, GFP) plasmid
Recombinant Anabaena variabilis (3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase (fabZ)